CMIC HOLDINGS Co., Ltd. leverages their experience of more than 30 years and know-how as a CRO(contract research organization) to provide customizable services to meet clients’ diverse needs. This page show-cases the key features of CMIC’s non-clinical study services, examples of disease models, and related case studies. We hope it serves as a reference when you select a CRO for non-clinical research.
CMIC HOLDINGS Co., Ltd. conducts high-quality non-clinical studies in compliance with Good Laboratory Practice (GLP) standards. The company provides highly reliable data in pharmacodynamic and pharmacokinetic studies by evaluating the safety under strict quality control.
With a strong track record in contract research, CMIC HOLDINGS Co., Ltd. offers flexible solutions tailored to a wide range of research needs. The company has collaborated with many pharmaceutical and biotech firms, providing extensive consulting and scientific support.
CMIC HOLDINGS Co., Ltd. offers a wide range of animal models for specific therapeutic areas. They have a laboratory infrastructure that allows for accurate evaluation efficacy, and new models can also be developed if requested.
It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.
However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.
Below are some examples of disease models offered at Ina Research.
Guinea pigs sensitized with OVA are used to evaluate drug effects on acute/chronic nasal reactions—such as rhinitis and nasal obstruction—induced by intranasal antigen administration, as well as on inflammatory cell infiltration in the nasal cavity.
Rats can also be used for efficacy studies on increased vascular permeability in the nasal mucosa.
Guinea pigs sensitized with OVA are used to examine drug effects on acute/chronic asthmatic reactions and airway obstruction induced by antigen inhalation, as well as on inflammatory cell infiltration in the airway lumen.
Mouse models are also available to investigate airway hyperresponsiveness and airway remodeling.
No case studies are currently listed on the official website.
Backed by extensive experience in non-clinical research, CMIC HOLDINGS Co., Ltd. provides comprehensive services ranging from new drug development planning to preparation of regulatory submission documents.
| Address | 1-1-1 Shibaura, Minato-ku, Tokyo, Japan |
|---|---|
| Tel | 03-6779-8000 |
| Website | https://www.cmicgroup.com/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.